Sign in to use this feature.

Years

Between: -

Subjects

remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline

Journals

remove_circle_outline
remove_circle_outline

Article Types

Countries / Regions

Search Results (4)

Search Parameters:
Keywords = herbal tablet formulation

Order results
Result details
Results per page
Select all
Export citation of selected articles as:
16 pages, 723 KiB  
Review
Hepatoprotective Effects of Liv.52 in Chronic Liver Disease Preclinical, Clinical, and Safety Evidence: A Review
by Chetan Kantharia, Munesh Kumar, Mukesh Kumar Jain, Lokendra Sharma, Lokesh Jain and Anish Desai
Gastroenterol. Insights 2023, 14(3), 293-308; https://doi.org/10.3390/gastroent14030021 - 31 Jul 2023
Cited by 6 | Viewed by 77732
Abstract
Chronic liver disease (CLD) is a growing concern worldwide. The common etiological factors include infection, alcohol abuse, exposure to hepatotoxic drugs, autoimmune disorders, and metabolic diseases. The chronic liver disease progresses to liver cirrhosis and its consequent complications. It is routinely managed by [...] Read more.
Chronic liver disease (CLD) is a growing concern worldwide. The common etiological factors include infection, alcohol abuse, exposure to hepatotoxic drugs, autoimmune disorders, and metabolic diseases. The chronic liver disease progresses to liver cirrhosis and its consequent complications. It is routinely managed by a combination of various therapies in combination with lifestyle modifications. The current literature supports the growing importance of the usage of herbal medicines in the management of CLD due to their efficacy and very low incidence of adverse effects. Liv.52 is a known polyherbal formulation and has been used for over 50 years in India and other countries. The evidence collected from preclinical and clinical studies supports the use of Liv.52 in symptomatic improvement and supportive treatment due to hepatitis (including Hepatitis B), alcoholic liver disease, non-alcoholic fatty liver disease (NAFLD), and non-alcoholic steatohepatitis (NASH) and hepatotoxicity due to drugs used in the treatment of tuberculosis. Liv.52 has also shown some preliminary hepatoprotective effects in patients with liver cirrhosis due to its potential antioxidant and anti-inflammatory effects. Both the syrup and tablet formulations are well tolerated and have shown a good safety profile. Liv.52 may be a favorable herbal choice for the management of CLD due to various etiologies. Full article
(This article belongs to the Section Liver)
Show Figures

Figure 1

11 pages, 627 KiB  
Article
Drug Formulation of Securigera securidaca Seed Extracts
by Mohamed E. M. Abdelbagi, Ghassab M. Al-Mazaideh, Adil Elhag Ahmed, Fuad Al-Rimawi, Haya Ayyal Salman, Abdulrahman Almutairi, Faraj Ahmad Abuilaiwi and Fadel Wedian
Processes 2023, 11(7), 1955; https://doi.org/10.3390/pr11071955 - 28 Jun 2023
Cited by 2 | Viewed by 1948
Abstract
S. securidaca seeds are reported to treat a variety of diseases; they contain multiple antidiabetic constituents and are widely used as anti-hyperglycemic, antibacterial, as well as anti-hyperlipidemic agents. The present work aimed to propose tablet formulations containing extracts of S. securidaca seeds in [...] Read more.
S. securidaca seeds are reported to treat a variety of diseases; they contain multiple antidiabetic constituents and are widely used as anti-hyperglycemic, antibacterial, as well as anti-hyperlipidemic agents. The present work aimed to propose tablet formulations containing extracts of S. securidaca seeds in an attempt to obtain antibacterial and anti-hyperglycemic formulations with a more efficient oral hypoglycemic impact, limited side effects, and higher patient compliance for the first time, resulting in multiple benefits. Tablet formulations were created by encapsulating granules from S. securidaca seed extracts with varying concentrations of sodium starch glycolate as a super-disintegrant (0–3%). The final formulations were examined for weight variation, solubility, hardness, water content, disintegration time, friability, drug content (trigonelline and diosgenin), and in vitro drug release. The S. securidaca tablet formulations completed the weight test because the percentage deviation in the personal tablet weight and mechanical resistance from the mean were identified to be within the average range. In accordance with the results, formulations containing diosgenin as well as trigonelline as a super-disintegrant were identified as the ideal formulations. The amount of the active substance released from the tablet (S. securidaca seed extract formulation) was consistent throughout the results with the standard methods recommended by the FDA (94.05%) for diosgenin and 87.25% for trigonelline after 45 min. The acceptable limit, according to the FDA, is not more than (N.L.T.) 80% after 45 min for phase #1. The present study aimed to obtain an optimized formula for S. securidaca extract tablets that met the requirements of a good pharmaceutical preparation according to the United States Pharmacopeia (USP) and National Formulary (NF). This has important implications for the development of novel, effective treatments and significantly advances the development of natural medicine. Our findings are expected to be of interest to researchers, clinicians, and other experts in this field of study. Based on these findings, it can be inferred that the formulation of S. securidaca seed extracts with appropriate and compatible herbal dosage forms has fewer side effects and is more effective than traditional treatments. Full article
(This article belongs to the Special Issue Bioactive Compounds from Natural Plants)
Show Figures

Figure 1

6 pages, 532 KiB  
Proceeding Paper
Formulation and Evaluation of Verdant Tablets Containing Saponin-Coalesced Silver Nanoparticles Got from Fenugreek Seed Extract
by Javesh Patil, Hamid Sayyed, Hemant Suryawanshi and Bhavika Patil
Chem. Proc. 2022, 8(1), 56; https://doi.org/10.3390/ecsoc-25-11765 - 14 Nov 2021
Cited by 5 | Viewed by 2367
Abstract
Presently, nanoparticles are in demand due to several applications. Commercially used metallic nanoparticles are usually comprised of synthetic chemicals. These chemicals are noxious and combustible. Current research had the objective to explore the advantages of nanoparticles using herbal material; hence, we developed silver [...] Read more.
Presently, nanoparticles are in demand due to several applications. Commercially used metallic nanoparticles are usually comprised of synthetic chemicals. These chemicals are noxious and combustible. Current research had the objective to explore the advantages of nanoparticles using herbal material; hence, we developed silver nanoparticles of aqueous extract of Trigonellafoenum-graecum (Fenugreek) seeds and formulated them into tablets. Fenugreek seeds contain steroidal sapogenins and are responsible for the reduction of blood cholesterol levels, control diabetes, enhance breast milk production, digestion aid, and helps in weight loss hence prepared formulation can be recommended in all the above cases. The pre-compression parameters evaluated for formulations are bulk density, tapped density, Carr’s index, Hausner’s ratio, and angle of repose, and the results are 0.16 gm/cc, 0.86 gm/cc, 14.16, ratio 1.13 and 32°, respectively; whereas post-compression parameters are weight variation, friability, hardness, thickness, and disintegration, and the results are 0.504 gm, 0.2%, 3.21 gm/cm2, 2.55 mm, and 7 min, respectively. Full article
Show Figures

Figure 1

16 pages, 6113 KiB  
Article
Multivariate Statistical Optimization of Tablet Formulations Incorporating High Doses of a Dry Herbal Extract
by Euichaul Oh, Uijung Kim, Beom-Jin Lee and Cheol Moon
Pharmaceutics 2019, 11(2), 79; https://doi.org/10.3390/pharmaceutics11020079 - 13 Feb 2019
Cited by 9 | Viewed by 4529
Abstract
The development of oral tablet formulation for herbal medicines has been restricted by large drug loadings and the poor physicochemical and mechanical properties of dry herbal extracts (DHEs). Herein, statistical experimental designs were applied to herbal tablet formulation development and optimization using Wuzi [...] Read more.
The development of oral tablet formulation for herbal medicines has been restricted by large drug loadings and the poor physicochemical and mechanical properties of dry herbal extracts (DHEs). Herein, statistical experimental designs were applied to herbal tablet formulation development and optimization using Wuzi Yanzong dry extract (WYE). The tablet disintegration time and hardness were identified as the critical quality attributes (CQAs) of the product. The tablet formulation was designed to achieve a high drug loading (50% or higher of WYE), shorter tablet disintegration time (less than 30 minutes), and suitable hardness (6.0 to 7.5 kp). A D-optimal mixture design was used to evaluate the effects of excipients on CQAs to minimize the risk compression failure and improve the tabletability in formulations containing WYE at 50% and 65% by weight. A partial least squares model was used to elucidate the multivariate relationships between a large number of formulation variables and product CQAs, and determine the maximum possible WYE loading. From overlaid plots of the effects of formulation variables on CQAs, it was found that a maximum WYE loading of 67% in tablet formulation satisfied the acceptance criteria of CQAs. In conclusion, this study shows that multivariate statistical tools are useful for developing tablet formulations containing high doses of herbal extracts and establishing control strategies that ensure product quality. Full article
Show Figures

Figure 1

Back to TopTop